NEWSALY™
    A World Of News, One Window.Saturday, September 5, 2026
    world

    US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know

    Mint
    September 5, 2026
    via Mint

    You're reading one story from Newsaly

    Newsaly brings together 60,000+ newspaper articles, 30,000+ podcasts and 10,000+ magazine articles from around the world.

    A World Of News, One Window.

    Explore Today's News
    US FDA approves AstraZeneca’s new breast cancer pill Etcamah: Dosage, high risk and side effects — All you need to know

    The drug, known as camizestrant, can be used in combination with other cancer medicines in patients who have a genetically driven form of metastatic breast cancer. AstraZeneca said camizestrant, which will go by the brand name ETCAMAH.

    Read the full story

    Explore More On Newsaly

    60,000+ Newspaper Articles

    Explore newspapers from around the world.

    Explore Newspapers

    30,000+ Podcasts

    Discover podcasts and listen to the latest conversations and news.

    Explore Podcasts

    10,000+ Magazine Articles

    Explore magazine articles from around the world.

    Explore Magazines

    Voices (0)

    Share a 15-second voice reaction. Voices automatically disappear after 10 days.

    Sign in to record a voice on this article.

    Be the first to share a voice on this article.